Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Colitis, Ulcerative, Crohn's Disease
Interventions: Vedolizumab SC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 47
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Wheat Ridge, Colorado + 44 more

Conditions: Pain, Postoperative, Analgesics, Opioid, Analgesics, Non-Narcotic, Physiological Effects of Drugs, Peripheral Nervous System Agents, Patient Satisfaction, Return to Work, Activity, Sexual
Interventions: Abdominal wall block with liposomal bupivicaine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Dermatitis
Interventions: Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab; Dietary Supplement · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more

Conditions: Diabetes Mellitus, Type 2
Interventions: CBT/CMT, Control group traditional primary care; Behavioral · Other
Lead sponsor: Community Wellness Center, West Linn, OR; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: West Linn, Oregon

Conditions: Glaucoma, OHT - Ocular Hypertension
Interventions: Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 30 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity
Interventions: filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, quality-of-life assessment, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 12 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Participants
Interventions: AMG 510, Digoxin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Cardiovascular Diseases, Pharmacists, Placebo Effect
Interventions: Virtual Statin Management (VSM); Other
Lead sponsor: University of Utah; Other
Eligibility: 21 Years to 80 Years
Enrollment: 898 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: Pirtobrutinib, Digoxin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pruritus
Interventions: Obeticholic acid, Linerixibat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: eszopiclone, zolpidem, placebo; Drug
Lead sponsor: Kettering Health Network; Other
Eligibility: 18 Years to 35 Years · Male only
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Kettering, Ohio

Conditions: Hepatitis, HIV/AIDS
Interventions: Boceprevir, Peg-Interferon-alfa 2B, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Healthy Volunteers, Pharmacologic Action
Interventions: Group 1 AZD3293, Group 2 AZD3293, Group 3 AZD3293, Group 1 Itraconazole, Group 2 Diltiazem, Group 3 Midazolam; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Sleep
Interventions: Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 440 mg (BAYH6689), Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 220 mg (BAYH6689), DPH 50mg, Ibuprofen 400 mg / Diphenhydramine citrate 76 mg; Drug
Lead sponsor: Bayer; Industry
Eligibility: 16 Years to 45 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy, NAFLD
Interventions: ASC41, Itraconazole, Phenytoin; Drug
Lead sponsor: Gannex Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Fibromyalgia
Interventions: Soy, Placebo; Dietary Supplement · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 76 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Nicotine Addiction
Interventions: Nicotine pouch: Low dose, Nicotine pouch: High dose, Low pH, High pH; Other
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 35 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Neuroendocrine Tumor, Carcinoid Syndrome
Interventions: Enterade®, Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0); Dietary Supplement · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy Participants
Interventions: AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Schizophrenia
Interventions: SEP-380135, Quinidine Gluconate; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: MDMA Discontinuation Syndrome
Interventions: 3,4-methylenedioxymethamphetamine or Placebo; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alcohol or Other Drugs Effects
Interventions: Alcohol + Caffeine Beverage, Alcohol + Caffeine-placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Non-Hodgkin's Lymphoma
Interventions: Mesna, Saline, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Mara Chambers; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections, Flaviviral Diseases, Flaviviridae Infections, RNA Virus Infections
Interventions: VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years to 35 Years
Enrollment: 2,428 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Edinburg, Texas • Houston, Texas

Search by objective public record fields.

A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Effect of Manual Medicine or Cognitive Behavioral Therapy With Chronic Uncontrolled Diabetes

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants

A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine

DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

Effect of Revival Soy on Fibromyalgia Pain

Effect of Product Characteristics on the Abuse Liability of Nicotine Pouches

Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women

Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.

Combined Effects of Alcohol and Caffeine

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents